Claes Andersson

An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia

Krali, Olga; Enblad, Anna Pia; Sulyaeva, Julia; Gogishvili, Dea et al.

Ingår i Communications Medicine, 2026

• DOI för An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia
• Ladda ner fulltext (pdf) av An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia

Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model

Mansoori, Sharmineh; Blom, Kristin; Andersson, Claes; Fryknäs, Mårten et al.

Ingår i Oncology Reports, 2026

• DOI för Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model
• Ladda ner fulltext (pdf) av Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model

Extensive analysis of pollutant interactions: Identification of deleterious synergistic effects at environmentally relevant dose levels using Drosophila and mammalian cells

Lagunas-Rangel, Francisco Alejandro; Åberg, Martin; Liao, Sifang; Espinelli-Amorim, Felippe et al.

Ingår i Science of the Total Environment, 2025

• DOI för Extensive analysis of pollutant interactions: Identification of deleterious synergistic effects at environmentally relevant dose levels using Drosophila and mammalian cells
• Ladda ner fulltext (pdf) av Extensive analysis of pollutant interactions: Identification of deleterious synergistic effects at environmentally relevant dose levels using Drosophila and mammalian cells

Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients

Enblad, Anna Pia; Krali, Olga; Gezelius, Henrik; Lundmark, Anders et al.

Ingår i HemaSphere, 2025

• DOI för Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients
• Ladda ner fulltext (pdf) av Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients

Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models

Selvin, Tove; Berglund, Malin; Akerstrom, Anders; Zia, Marco et al.

Ingår i SLAS TECHNOLOGY, 2024

• DOI för Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models
• Ladda ner fulltext (pdf) av Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models

An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia

Krali, Olga; Enblad, Anna Pia; Sulyaeva, Julia; Gogishvili, Dea et al.

Ingår i Communications Medicine, 2026

• DOI för An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia
• Ladda ner fulltext (pdf) av An integrative molecular map of pediatric B-cell precursor acute lymphoblastic leukemia

Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model

Mansoori, Sharmineh; Blom, Kristin; Andersson, Claes; Fryknäs, Mårten et al.

Ingår i Oncology Reports, 2026

• DOI för Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model
• Ladda ner fulltext (pdf) av Characterization of the anticancer effect of mebendazole and its interaction with standard cytotoxic drugs in patient tumor cells ex vivo and in an in vivo mouse model

Extensive analysis of pollutant interactions: Identification of deleterious synergistic effects at environmentally relevant dose levels using Drosophila and mammalian cells

Lagunas-Rangel, Francisco Alejandro; Åberg, Martin; Liao, Sifang; Espinelli-Amorim, Felippe et al.

Ingår i Science of the Total Environment, 2025

• DOI för Extensive analysis of pollutant interactions: Identification of deleterious synergistic effects at environmentally relevant dose levels using Drosophila and mammalian cells
• Ladda ner fulltext (pdf) av Extensive analysis of pollutant interactions: Identification of deleterious synergistic effects at environmentally relevant dose levels using Drosophila and mammalian cells

Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients

Enblad, Anna Pia; Krali, Olga; Gezelius, Henrik; Lundmark, Anders et al.

Ingår i HemaSphere, 2025

• DOI för Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients
• Ladda ner fulltext (pdf) av Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients

Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models

Selvin, Tove; Berglund, Malin; Akerstrom, Anders; Zia, Marco et al.

Ingår i SLAS TECHNOLOGY, 2024

• DOI för Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models
• Ladda ner fulltext (pdf) av Exploratory insights from the immuno-oncology hollow fiber assay: A pilot approach bridging In Vitro and In Vivo models

Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment

Selvin, Tove; Berglund, Malin; Lenhammar, Lena; Lindskog, Magnus et al.

Ingår i BMC Pharmacology & Toxicology, 2024

• DOI för Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment
• Ladda ner fulltext (pdf) av Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment

Comparison of high-throughput single-cell RNA-seq methods for ex vivo drug screening

Gezelius, Henrik; Enblad, Anna Pia; Lundmark, Anders; Åberg, Martin et al.

Ingår i NAR Genomics and Bioinformatics, 2024

• DOI för Comparison of high-throughput single-cell RNA-seq methods for ex vivo drug screening
• Ladda ner fulltext (pdf) av Comparison of high-throughput single-cell RNA-seq methods for ex vivo drug screening

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death

Selvin, Tove; Berglund, Malin; Lenhammar, Lena; Jarvius, Malin et al.

Ingår i BMC Cancer, 2023

• DOI för Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death
• Ladda ner fulltext (pdf) av Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death

Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases

Cashin, Peter; Söderström, Maria; Blom, Kristin; Artursson, Sara et al.

Ingår i British Journal of Surgery, s. 1080-1083, 2023

• DOI för Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases
• Ladda ner fulltext (pdf) av Ex vivo assessment of chemotherapy sensitivity of colorectal cancer peritoneal metastases

Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients

Andersson, Claes; Ye, Jiawei; Blom, Kristin; Fryknäs, Mårten et al.

Ingår i Anti-Cancer Drugs, s. 92-102, 2023

• DOI för Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
• Ladda ner fulltext (pdf) av Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients

Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome

Bjersand, Kathrine; Blom, Kristin; Sundström Poromaa, Inger; Stålberg, Karin et al.

Ingår i International Journal of Oncology, 2022

• DOI för Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome
• Ladda ner fulltext (pdf) av Ex vivo assessment of cancer drug sensitivity in epithelial ovarian cancer and its association with histopathological type, treatment history and clinical outcome

Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model

Selvin, Tove; Fasterius, Erik; Jarvius, Malin; Fryknäs, Mårten et al.

Ingår i Scientific Reports, 2022

• DOI för Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model
• Ladda ner fulltext (pdf) av Single-cell transcriptional pharmacodynamics of trifluridine in a tumor-immune model

Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma

Nyberg, Frida; Blom, Kristin; Selvin, Tove; Rudfeldt, Jakob et al.

Ingår i Scientific Reports, 2022

• DOI för Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma
• Ladda ner fulltext (pdf) av Sorafenib and nitazoxanide disrupt mitochondrial function and inhibit regrowth capacity in three-dimensional models of hepatocellular and colorectal carcinoma

Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Byrgazov, Konstantin; Lind, Thomas; Rasmusson, Annica J.; Andersson, Claes et al.

Ingår i Bone Reports, 2021

• DOI för Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes

Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide

Byrgazov, Konstantin; Andersson, Claes; Salzer, Benjamin; Bozsaky, Eva et al.

Ingår i Therapeutic Advances in Medical Oncology, 2020

• DOI för Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
• Ladda ner fulltext (pdf) av Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide

Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Andersson, Claes; Selvin, Tove; Blom, Kristin; Rubin, Jenny et al.

Ingår i Scientific Reports, 2020

• DOI för Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
• Ladda ner fulltext (pdf) av Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Blom, Kristin; Eriksson, Jenny; Berglund, Malin; Jarvius, Malin et al.

Ingår i BMC Research Notes, 2019

• DOI för Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
• Ladda ner fulltext (pdf) av Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Self-tuning density estimation based on Bayesian averaging of adaptive kernel density estimations yields state-of-the-art performance

Bäcklin, Christofer; Andersson, Claes; Gustafsson, Mats G

Ingår i Pattern Recognition, s. 133-143, 2018

• DOI för Self-tuning density estimation based on Bayesian averaging of adaptive kernel density estimations yields state-of-the-art performance

Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism

Kashif, Muhammad; Andersson, Claes; Mansoori, Sharmineh; Larsson, Rolf et al.

Ingår i Oncotarget, s. 103952-103967, 2017

• DOI för Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism
• Ladda ner fulltext (pdf) av Bliss and Loewe interaction analyses of clinically relevant drug combinations in human colon cancer cell lines reveal complex patterns of synergy and antagonism

Targeting tumor cells based on Phosphodiesterase 3A expression

Nazir, Madiha; Senkowski, Wojciech; Nyberg, Frida; Blom, Kristin et al.

Ingår i Experimental Cell Research, s. 308-315, 2017

• DOI för Targeting tumor cells based on Phosphodiesterase 3A expression

The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

Blom, Kristin; Senkowski, Wojciech; Jarvius, Malin; Berglund, Malin et al.

Ingår i Immunopharmacology and immunotoxicology, s. 199-210, 2017

• DOI för The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis

Blom, Kristin; Nygren, Peter; Larsson, Rolf; Andersson, Claes R.

Ingår i SLAS TECHNOLOGY, s. 306-314, 2017

• DOI för Predictive Value of Ex Vivo Chemosensitivity Assays for Individualized Cancer Chemotherapy: A Meta-Analysis

Large-scale ligand-based predictive modelling using support vector machines

Alvarsson, Jonathan; Lampa, Samuel; Schaal, Wesley; Andersson, Claes et al.

Ingår i Journal of Cheminformatics, 2016

• DOI för Large-scale ligand-based predictive modelling using support vector machines
• Ladda ner fulltext (pdf) av Large-scale ligand-based predictive modelling using support vector machines

Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia

Österroos, Albin; Kashif, Muhammad; Haglund, Caroline; Blom, Kristin et al.

Ingår i Biochemical Pharmacology, s. 40-49, 2016

• DOI för Combination screening in vitro identifies synergistically acting KP372-1 and cytarabine against acute myeloid leukemia

Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy

Blom, Kristin; Nygren, Peter; Alvarsson, Jonathan; Larsson, Rolf et al.

Ingår i JALA, s. 178-187, 2016

• DOI för Ex Vivo Assessment of Drug Activity in Patient Tumor Cells as a Basis for Tailored Cancer Therapy

In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index

Kashif, Muhammad; Andersson, Claes; Hassan, Sadia; Karlsson, Henning et al.

Ingår i Scientific Reports, 2015

• DOI för In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index
• Ladda ner fulltext (pdf) av In vitro discovery of promising anti-cancer drug combinations using iterative maximisation of a therapeutic index

Benchmarking Study of Parameter Variation When Using Signature Fingerprints Together with Support Vector Machines

Alvarsson, Jonathan; Eklund, Martin; Andersson, Claes; Carlsson, Lars et al.

Ingår i Journal of Chemical Information and Modeling, s. 3211-3217, 2014

• DOI för Benchmarking Study of Parameter Variation When Using Signature Fingerprints Together with Support Vector Machines

A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant In Vitro Multicompound Analyses

Kashif, Muhammad; Andersson, Claes; Åberg, Magnus; Nygren, Peter et al.

Ingår i Molecular Cancer Therapeutics, s. 1964-1976, 2014

• DOI för A Pragmatic Definition of Therapeutic Synergy Suitable for Clinically Relevant In Vitro Multicompound Analyses

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

Fryknäs, Mårten; Gullbo, Joachim; Wang, Xin; Rickardson, Linda et al.

Ingår i BMC Cancer, s. 374, 2013

• DOI för Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
• Ladda ner fulltext (pdf) av Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance

Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines

Sooman, Linda; Ekman, Simon; Andersson, Claes; Kultima, Hanna Göransson et al.

Ingår i Cancer Chemotherapy and Pharmacology, s. 329-340, 2013

• DOI för Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines

A strand specific high resolution normalization method for chip-sequencing data employing multiple experimental control measurements

Enroth, Stefan; Andersson, Claes R.; Andersson, Robin; Wadelius, Claes et al.

Ingår i Algorithms for Molecular Biology, s. 2, 2012

• DOI för A strand specific high resolution normalization method for chip-sequencing data employing multiple experimental control measurements
• Ladda ner fulltext (pdf) av A strand specific high resolution normalization method for chip-sequencing data employing multiple experimental control measurements

Synergistic Effects of PI3K or P38 MAPK Inhibition in Combination With Vandetanib Treatment in Glioblastoma Cells

Sooman, Linda; Ekman, Simon; Andersson, Claes; Johansson, Fredrik et al.

Ingår i European Journal of Cancer, 2012

• DOI för Synergistic Effects of PI3K or P38 MAPK Inhibition in Combination With Vandetanib Treatment in Glioblastoma Cells

Brunn: an open source laboratory information system for microplates with a graphical plate layout design process

Alvarsson, Jonathan; Andersson, Claes; Spjuth, Ola; Larsson, Rolf et al.

Ingår i BMC Bioinformatics, 2011

• DOI för Brunn: an open source laboratory information system for microplates with a graphical plate layout design process
• Ladda ner fulltext (pdf) av Brunn: an open source laboratory information system for microplates with a graphical plate layout design process

Multiplexed Homogeneous Proximity Ligation Assays for High-throughput Protein Biomarker Research in Serological Material

Lundberg, Martin; Thorsen, Stine Buch; Assarsson, Erika; Villablanca, Andrea et al.

Ingår i Molecular & Cellular Proteomics, 2011

• DOI för Multiplexed Homogeneous Proximity Ligation Assays for High-throughput Protein Biomarker Research in Serological Material

Improving Bayesian credibility intervals for classifier error rates using maximum entropy empirical priors

Gustafsson, Mats G.; Wallman, Mikael; Wickenberg-Bolin, Ulrika; Göransson, Hanna et al.

Ingår i Artificial Intelligence in Medicine, s. 93-104, 2010

• DOI för Improving Bayesian credibility intervals for classifier error rates using maximum entropy empirical priors

Revealing cell cycle control by combining model-based detection of periodic expression with novel cis-regulatory descriptors

Andersson, Claes R.; Hvidsten, Torgeir R.; Isaksson, Anders; Gustafsson, Mats G. et al.

Ingår i BMC Systems Biology, s. 45, 2007

• DOI för Revealing cell cycle control by combining model-based detection of periodic expression with novel cis-regulatory descriptors

In vitro drug sensitivity-gene expression correlations involve a tissue of origin dependency

Andersson, Claes R.; Fryknäs, Mårten; Rickardson, Linda; Larsson, Rolf et al.

Ingår i Journal of chemical information and modeling, s. 239-248, 2007

• DOI för In vitro drug sensitivity-gene expression correlations involve a tissue of origin dependency

Bayesian detection of periodic mRNA time profiles withouth use of training examples

Andersson, Claes R.; Isaksson, Anders; Gustafsson, Mats G.

Ingår i BMC Bioinformatics, s. 63, 2006

• DOI för Bayesian detection of periodic mRNA time profiles withouth use of training examples

Quantitative Chemogenomics: Machine-Learning Models of Protein-Ligand Interaction

Andersson, Claes R.; Gustafsson, Mats G.; Strömbergsson, Helena

Ingår i Current Topics in Medicinal Chemistry, s. 1978-1993, 2011

• DOI för Quantitative Chemogenomics: Machine-Learning Models of Protein-Ligand Interaction